Intelligent Bio Solutions reports 98.2% accuracy in clinical study of fingerprint codeine screening device
INBS•FDA filing plans and market entry
- Data collection is finished, clearing a key hurdle for a planned FDA 510(k) submission in September 2026.
- Management expects the filing to support planned entry into the U.S. market following FDA clearance.
Clinical study results for fingerprint codeine screening device
Intelligent Bio Solutions reported completed U.S. clinical study results for its fingerprint-based drug screening system targeting codeine.
- Findings showed stronger overall performance versus its prior study, supporting reliability across multiple clinical sites.
